Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | HTT | P42858 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | GFER | P55789 | 1/20 | 0.54 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25839446 | 0.84 | SMN1; SMN2 (0.51) | MAPTALDH1A1HTTLMNASMN1; SMN2 | |
| SCHEMBL14924441 | 0.81 | AKR1C3 (0.65) | MAPTALDH1A1HTTLMNASMN1; SMN2 | |
| SCHEMBL16994768 | 0.81 | MEN1 (0.63) | MAPTALDH1A1HTTLMNASMN1; SMN2 | |
| SCHEMBL7838255 | 0.81 | HTT (0.61) | MAPTALDH1A1HTTLMNASMN1; SMN2 | |
| SCHEMBL22542013 | 0.80 | HTT (0.59) | MAPTALDH1A1HTTLMNASMN1; SMN2 | |
| SCHEMBL12916359 | 0.80 | HTT (0.59) | MAPTALDH1A1HTTLMNASMN1; SMN2 | |
| SCHEMBL25840501 | 0.78 | MAPT (0.64) | MAPTALDH1A1HTTLMNASMN1; SMN2 | |
| SCHEMBL14683454 | 0.78 | ALDH1A1 (0.61) | MAPTALDH1A1HTTLMNASMN1; SMN2 | |
| SCHEMBL22542017 | 0.77 | HTT (0.57) | MAPTALDH1A1HTTLMNASMN1; SMN2 | |
| SCHEMBL12047642 | 0.77 | MAPT (0.61) | MAPTALDH1A1HTTLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210188844-A1 | FUSED PYRIMIDINE PYRIDINONE COMPOUNDS AS JAK INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210188844-A1 | FUSED PYRIMIDINE PYRIDINONE COMPOUNDS AS JAK INHIBITORS | JAK3, JAK1, JAK2 | MAPT 3409/4885ALDH1A1 2446/4885HTT 4020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.